SCHEMBL570533

SCHEMBL570533

Cc1cccc2[nH]nc(C(=O)O)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 2/20 0.50
MAPK1 P28482 1/20 0.50
MAP2K4 P45985 1/20 0.50
MAPKAPK2 P49137 1/20 0.50
MAPK6 Q16659 1/20 0.50
KDM4E B2RXH2 2/20 0.45
YTHDC1 Q96MU7 1/20 0.45
STAT3 P40763 1/20 0.45
HIF1A Q16665 1/20 0.45
CTNNB1 P35222 1/20 0.44
WNT3A P56704 1/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FLT3 P36888 4/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CCNA1 P78396 1/20 0.43
ADRA2A P08913 1/20 0.43
MAP4K1 Q92918 1/20 0.43
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9444673 0.98 HAO1 (0.49) HAO1MAPK1MAP2K4MAPKAPK2MAPK6
SCHEMBL3779528 0.85 MAP2K4 (0.49) HAO1MAPK1MAP2K4MAPKAPK2MAPK6
SCHEMBL2723270 0.85 MAP2K4 (0.49) HAO1MAPK1MAP2K4MAPKAPK2MAPK6
SCHEMBL1967918 0.81 GPR17 (0.43) HAO1MAPK1MAP2K4MAPK6KDM4E
SCHEMBL28497966 0.81 PARP1 (0.45) HAO1MAPK1MAP2K4MAPK6KDM4E
SCHEMBL28503102 0.79 PARP1 (0.44) HAO1MAPK1MAP2K4MAPK6KDM4E
SCHEMBL7374273 0.79 GAA (0.54) MAP2K4HCAR2
SCHEMBL28192986 0.79 MAPK1 (0.54) HAO1MAPK1MAP2K4MAPKAPK2MAPK6
SCHEMBL16240884 0.79 CTNNB1 (0.44) KDM4EYTHDC1STAT3HIF1ACTNNB1
SCHEMBL492585 0.79 CTNNB1 (0.48) MAPKAPK2KDM4ESTAT3HIF1ACTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007054784-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF GRANISETRON HYDROCHLORIDE ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2007-05-18 WO claimed
CN-1260216-C Method for synthesizing 1-methyl-benzdiazole-3-formic acid UNIV WUHAN (CN) 2006-06-21 CN claimed
EP-0772613-A2 PROCESS FOR THE PRODUCTION OF AMINOAZOBICYCLOALKANES FROM OXIMES SMITHKLINE BEECHAM PLC (GB) 1997-05-14 EP claimed
WO-1996003401-A2 PROCESS FOR THE PRODUCTION OF AMINOAZOBICYCLOALKANES FROM OXIMES SMITHKLINE BEECHAM PLC (GB) 1996-02-08 WO claimed
CN-109796410-A A kind of synthetic method of 5- substituted indazole -3- carboxylic acid 药雅科技(上海)有限公司 2019-05-24 CN disclosed
US-20190040016-A1 INDOLE AND INDAZOLE COMPOUNDS AND THERAPEUTIC USES THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-02-07 US disclosed
EP-3433235-A1 INDOLE AND INDAZOLE COMPOUNDS AND THERAPEUTIC USES THEREOF Regents of the University of Minnesota (US) 2019-01-30 EP disclosed
WO-2017165300-A1 INDOLE AND INDAZOLE COMPOUNDS AND THERAPEUTIC USES THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2017-09-28 WO disclosed
CN-105061313-B Androgen receptor modulating compounds 奥赖恩公司 2017-07-18 CN disclosed
EP-2812346-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV Graffinity Pharmaceuticals GmbH (DE) 2014-12-17 EP disclosed
EP-2651906-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE Cocrystal Discovery, Inc. (US) 2013-10-23 EP disclosed
WO-2013117707-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-08-15 WO disclosed
EP-2170874-A2 NOVEL COMPOUNDS AND THEIR USE Orchid Research Laboratories Limited (IN) 2010-04-07 EP disclosed
WO-2009001192-A2 NOVEL COMPOUNDS AND THEIR USE ORCHID RESEARCH LABORATORIES LIMITED (IN) 2008-12-31 WO disclosed
WO-2007088557-A1 PROCESS FOR HIGHLY PURE CRYSTALLINE GRANISETRON BASE NATCO PHARMA LIMITED (IN) 2007-08-09 WO disclosed
EP-1487833-A1 PROCESS FOR PREPARING A PHARMACEUTICALLY ACTIVE COMPOUND (GRANISETRON) LABORATORIOS VITA, S.A. (ES) 2004-12-22 EP disclosed
WO-2003080606-A1 PROCESS FOR PREPARING A PHARMACEUTICALLY ACTIVE COMPOUND (GRANISETRON) LABORATORIOS VITA, S.A. (ES) 2003-10-02 WO disclosed
US-5331006-A Cholecystokinin, antisecretory agents WARNER-LAMBERT COMPANY (US) 1994-07-19 US disclosed
EP-0528026-A1 NEW MESO-AZACYCLIC AROMATIC ACID AMIDES AND ESTERS AS NOVEL SEROTONERGIC AGENTS G.D. SEARLE & CO. (US) 1993-02-24 EP disclosed
WO-1992004025-A1 AMINO ACID ANALOGS AS CCK ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1992-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040016-A1 INDOLE AND INDAZOLE COMPOUNDS AND THERAPEUTIC USES THEREOF INMT, IDO1, IDO2 HAO1 3843/4885MAPK1 4250/4885MAP2K4 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.